SUMMARY ......................................................... i
TECHNETIUM CHEMISTRY AND RADIOPHARMACEUTICALS: I
(Session 1)
Technetium-99m radiopharmaceuticals: Current situation
and perspectives ................................................ 3
A.M. Verbruggen
99mTc labelled minigastrin for tumour targeting: Optimization
of labelling and peptide sequence .............................. 21
E. von Guggenberg, M.P. Béhé, C. Decristoforo
Design and synthesis of isoniazide mimetic conjugated with
DTPA, potential ligand of novel radiopharmaceutical and
contrast agent for medical imaging, bis (amide) of
diethylenetriaminepentaacetic acid: DTPA-Bis(INH) .............. 31
A.K. Mishra, P. Panwar, K. Chuttani, N. Kumar, P. Mishra,
R.K. Sharma, R. Sharma
Antimicrobial peptide 99mTc-UBI 29-41 for infection
diagnosis: Kit formulation and a preliminary clinical study .... 43
G. Rodríguez, P. Oliver, J. Vilar, V. Trindade, A. R0bles,
A. Löpez, G. Lago, H. Baiter, M.M. Welling, E.K.J. Pauwels
TECHNETIUM CHEMISTRY AND RADIOPHARMACEUTICALS: II
(Session 2)
Preparation and evaluation of third generation technetium-99m
radiopharmaceuticals ........................................... 55
G. Ferro-Flores, C. Arteaga de Murphy, F. de M. Ramirez,
M. Pedraza-Löpez, J. Rodríguez-Cortés, L. Meléndez-Alafort
Detection of deep venous thrombosis in an experimental
animal model using radioactive labelled tirofiban
GPIIb/IIIa inhibitor ........................................... 65
E. Janevik-Ivanovska, I. Djorgoski, A. Andonovski,
V. Milenkov, S. Miceva-Ristevska, G. Janoki
Preparation of in-house Dextran and its clinical applications
in sentinel node studies, Siriraj Hospital ..................... 83
N. Tojinda, S. Chiewvit, B. Khiewvan, S. Dumrongpisutikul,
A. Ratanawichitrasin, S. Taweepraditpol
Comparative study of 99mTc-EMB and native EMB and the role
of 99mTc-EMB in resistant mycobacterial imaging ................ 95
N. Singh, A.K. Singh, A. Bhatnagar, G. Mittal,
T. Ravindranath
TECHNETIUM CHEMISTRY AND RADIOPHARMACEUTICALS: III
(Session 3)
Technetium radiopharmaceuticals: Applications in nuclear
cardiology .................................................... 103
R.M.T. Giubbini
Imaging oncogene mRNA for early diagnosis of cancer ........... 113
N. Shanthly, M.R. Aruva, K. Zhang, C.A. Cardi,
T. Xiobing, E. Wickstrom, M.L. Thakur
Synthesis and evaluation of 99mTc-Kanamycin and 99mTc-
Isoniazid for infection imaging ............................... 149
M. Jehangir, A. Mushtaq, S.A. Malik, S. Roohi
Preparation of 99mTc-pentavalent DMSA and its uptake by
benign bone diseases .......................................... 167
N. Boucekkine, S.A. Zemoul, F. Mouas, R. Benlabgaa,
S. Hanzal, A. Khelifa, F. Mechken, M. Habeche,
K. Bellazoug, B. Benchelaghem, S.E. Bouyoucef
NOVEL TECHNETIUM CHEMISTRY AND RADIOPHARMACEUTICALS: I
(Session 4)
What role for 99mTc radiopharmaceuticals in the age of
molecular imaging? ............................................ 171
A. Duatti
99mTc EDDA/HYNIC-TOC: A suitable radiopharmaceutical for
radioguided surgery of neuroendocrine tumours ................. 183
J. Fettich, S. Repse, M. Snoj, M. Zitko-Krhin,
S. Markovic
Comparative in vitro and in vivo evaluation of a series of
novel bombesin-like peptides .................................. 185
E. Gourni, P. Bouziotis, M. Paravatou, S. Xanthopoulos,
S.C. Archimandritis, A.D. Varvarigou, M. Fani, G. Loudos
[99mTcN]-N-benzyl piperidine dithiocarbonate: A potential
sigma receptor imaging agent .................................. 197
D. Satpati, K. Bapat, S. Banerjee, K. Kothari,
H.D. Sarma, M. Venkatesh
99mTc labelled peptide Fl 1: A new potential αvβ3 integrin
antagonist for scintigraphic detection of tumours ............. 205
A. Perera, A. Prats, A. Hernández, O. Reyes, M. Bequet,
N. Santiago, R. Leyva, E. Fernandez, G. Pimentel
HYNIC-TOC labelled with 99mTc via an instant kit
formulation: Preclinical results .............................. 217
M. Ciavaro, E. Obenaus, G. Fiszman, S.G. de Castiglia
INDIGENOUS CAPACITY BUILDING IN RADIOPHARMACEUTICALS
(Session 5)
Indigenous capacity building in radiopharmaceuticals:
Saudi Arabian experience ...................................... 227
M.M. Vora
Trends in indigenous radioisotope and radiopharmaceutical
production in Bangladesh ...................................... 241
M.Z. Abedin, M.A. Haque
Experience in the production of Pakgen 99Mo-99mTc
generators .................................................... 249
M.M. Ishfaq, H. Nizakat, K.M. Bashar, M. Jehangir
BIONT — A new centre for PET radiopharmaceuticals production
in central Europe ............................................. 265
P. Rajec, F. Macásek, P. Kovác
Capacities and current activities of the Cyclotron and
Nuclear Medicine Department at NRCAM .......................... 271
K.K. Moghaddam
REACTOR BASED RADIONUCLIDES AND GENERATORS
(Session 6)
Production of therapeutic radionuclides in medium flux
research reactors ............................................. 285
M. Venkatesh, S. Chakraborty
The continuing important role of high flux research reactors
for production of therapeutic radioisotopes ................... 301
F.F. Knapp, Jr., S. Mirzadeh, M.A. Garland
Technological line for the production of carrier free 188Re
in the form of sterile isotonic solution of sodium
perrhenate(VII) ............................................... 323
E. Iller, Z. Zelek, M. Konior, K. Sawlewicz,
J. Staniszewska, R. Mikolajczak, U. Karczmarczyk
Hydroxyapatite based 99Mo-99mTc and 188W-188Re generator
systems ....................................................... 333
F. Monroy-Guzmán, V.E. Badillo-Almaraz, J.A.
Flores de la Torre, J. Cosgrove, F.F. Knapp, Jr.
Fostering development efforts towards (a) small scale local
production of 99Mo from LEU targets and (b) gel generator
for 99mTc using (n,γ)99Mo: The IAEA role ...................... 349
N. Ramamoorthy, I. Goldman, P. Adelfang
NOVEL TECHNETIUM CHEMISTRY AND RADIOPHARMACEUTICALS: II
(Session 7)
Novel technetium chemistry and radiopharmaceuticals:
Tc(V), Tc(III) or Tc(I) — which way to go for keeping
Tc radiopharmaceuticals alive? ................................ 355
R. Alberto, S. Kunze, S. Mundwiler, B. Spingler
New 99mTc-cytectrine piperidine compound as a specific
brain imaging agent ........................................... 365
M. Saidi, M. Trabelsi, A. Mekni
Tricarbonyltechnetium(I) complexes with neutral bidentate
ligands — N-methyl-2-pyridinecarboamide and
N-methyl-2-pyridinecarbothioamide: Experimental and
theoretical studies ........................................... 367
J. Narbutt, M. Zasepa-Lyczko, M. Czerwinski, R. Schibli
Modified bombesin analogue with technetium tricarbonyl
precursor as prostatic radiodiagnostic agent .................. 375
B.L. Faintuch, E. Muramoto, L. Morganti, R.M.
Chura-Chambi, N. Nascimento, E.G. Garayoa, P.
Blauenstein, P.A. Schubiger
Synthesis and characterization of 99mTc-metomidate as the
99mTc(I)-tricarbonyl-(R)-bipyridinyl-MTO-conjugate ............ 383
R. Schibli, M. Stichelberger, F. Hammerschmidt, M.L.
Berger, I. Zolle
Direct labelling of Lipiodol with [188Re(CO)3]-chelates ....... 395
M.M. Saw, F.X. Sundram, T.S. Andy Hor, Y.Y. Kai,
R. Alberto
|
